Overview

ATXA Therapeutics Limited is focusing on late-stage preclinical and clinical development of novel small molecule drugs to treat Pulmonary Arterial Hypertension (PAH). Headquartered in Dublin, Ireland, ATXA Therapeutics is a spin-out company from University College Dublin whose primary focus is to advance clinical trials and to secure marketing authorization of novel therapies for the treatment of PAH, serving a previously unmet medical need by offering improved treatment options to the prescribing physician and new hope for the PAH patient. Founded by Professor Therese Kinsella, ATXA was incorporated in May 2015 and is the culmination of over 20 years of extensive research and over €15m of grant funding and a proven track record in understanding of the biology and signalling of the human prostanoid receptors in the cardiovascular disease and oncology setting. Supported with funding from a number of technology and commercialization development grants from Enterprise Ireland and Science Foundation Ireland, ATXA has developed a series of novel, highly selective small molecule drugs, and has identified and validated their potential use in a number of target disease indications including thrombosis/cardiovascular, oncology, anti-inflammatory and, in particular, in PAH. ATXA Therapeutics Ltd will advance the late-stage development of their novel therapies that display substantial improvements over the existing standard-of-care, addressing critical unmet medical needs for efficacious new therapies to treat PAH. ATXA Therapeutics Ltd. is a company on a mission... to offer new hope to the PAH patient.